Clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway.
ALX Oncology Holdings Inc., headquartered in South San Francisco, California, is a dynamic clinical-stage immuno-oncology company dedicated to advancing innovative therapies for patients battling cancer. At the forefront of its portfolio is ALX148, a potent CD47 blocking therapeutic currently undergoing Phase 1b/2 clinical trials. ALX148 shows promise for the treatment of myelodysplastic syndromes, acute myeloid leukemia, non-Hodgkin's lymphoma, and various solid tumors, including head and neck squamous cell carcinoma, HER2-positive gastric/gastroesophageal junction carcinoma, and HER2-expressing breast cancer.
In addition to ALX148, ALX Oncology is actively developing ALTA-002, a SIRPa TRAAC designed to enhance the innate and adaptive immune responses against cancer. These preclinical advancements underscore the company's commitment to expanding its therapeutic pipeline and pioneering new avenues in cancer immunotherapy.
Through strategic collaborations, ALX Oncology has partnered with industry leaders such as Merck for Phase 2 trials evaluating ALX148 in combination with pembrolizumab for head and neck cancer treatment. Collaborations with Zymeworks and Tallac Therapeutics further bolster its efforts in exploring innovative treatment modalities, including combinations with bispecific antibodies and novel cancer immunotherapeutics.
Founded in 2015, ALX Oncology Holdings Inc. continues to leverage its expertise and partnerships to accelerate the development and commercialization of transformative cancer therapies. With a strong focus on scientific innovation and patient-centric approaches, the company aims to address critical unmet needs in oncology and improve outcomes for cancer patients globally.